ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

Market Cap	6.03B +126.7%
Revenue (ttm)	638.35M +32.5%
Net Income	120.09M +29.8%
EPS	0.75 +27.6%
Shares Out	157.39M
PE Ratio	51.37
Forward PE	33.32
Dividend	0.06 (0.16%)
Ex-Dividend Date	Nov 17, 2025

Volume	3,433,884
Average Volume	2,342,962
Open	38.66
Previous Close	38.94
Day's Range	38.10 - 38.94
52-Week Range	15.88 - 47.97
Beta	0.78
RSI	44.29
Earnings Date	Apr 24, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. Che...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,450
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688117

Financial Performance

In 2024, ChengDu ShengNuo Biotec's revenue was 456.07 million, an increase of 4.84% compared to the previous year's 435.02 million. Earnings were 50.02 million, a decrease of -28.88%.